Abstract

Acadia Healthcare will report quarterly results on February 25, 2026 Pre-Market; this preview synthesizes the latest reported figures, current-quarter forecasts, and recent institutional commentary to frame expectations for revenue, profitability, and adjusted EPS into the print.

Market Forecast

Consensus projections compiled for the current quarter point to revenue of $800.06 million, an increase of 2.71% year over year, with EPS expected at $0.06, down 91.89% year over year; EBIT is modeled at $51.16 million, implying an approximate EBIT margin of 6.40% and a year-over-year decline of 59.98%. Forecasts do not include a formal gross profit margin or net profit margin outlook; if management provides these on the call, they will be key markers for margin stabilization into the year.

Within the core revenue mix, payer revenues remain led by Medicaid, followed by Commercial and Medicare, and management execution this quarter will center on sustaining volumes and pricing while managing operating costs and liability-related expenses. The most promising near-term contributor remains the Commercial payer channel at $211.88 million last quarter by revenue, where price realization can provide incremental margin support; segment-level year-over-year growth was not disclosed, though total company revenue expanded 4.41% year over year in the same period.

Last Quarter Review

Acadia Healthcare delivered revenue of $851.57 million with a gross profit margin of 42.16%, GAAP net income attributable to shareholders of $36.25 million yielding a 4.26% net profit margin, and adjusted EPS of $0.72, down 20.88% year over year.

The company posted a modest beat versus consensus, with revenue exceeding estimates by $5.84 million and adjusted EPS topping forecasts by $0.05, while quarter-on-quarter net income improved by 20.31% and payer mix remained consistent with Medicaid as the largest contributor. Payer revenues were led by Medicaid at $484.17 million, followed by Commercial at $211.88 million and Medicare at $125.54 million; total company revenue rose 4.41% year over year.

Current Quarter Outlook

Core revenue drivers and profitability levers

The current quarter setup reflects modest top-line expansion with heightened attention on profitability. With revenue modeled at $800.06 million, the forecast implies sequential revenue normalization after a seasonally strong prior quarter while still delivering a 2.71% year-over-year increase. On earnings, a consensus EPS of $0.06 points to a meaningful year-over-year decline of 91.89%, and the $51.16 million EBIT estimate implies a 6.40% EBIT margin for the period. The gap between healthy top-line growth and sharply lower earnings underscores the importance of non-revenue factors—liability-related costs, labor, and operating efficiency indices—to this quarter’s margin cadence.

The ability to preserve gross profit dollars and margin from last quarter’s 42.16% level will hinge on utilization patterns, payer mix, and the pace of contract rate realization. Operating discipline around staffing—especially a continued transition away from premium labor and tighter management of overtime—remains central to supporting fixed-cost absorption as volumes evolve. In parallel, revenue integrity initiatives tied to documentation, coding accuracy, and authorizations are necessary to translate volume into net revenue capture without disrupting throughput.

The EBIT forecast, down 59.98% year over year, embeds a conservative stance on operating expense items that are not purely volume-driven. This places emphasis on cost stewardship: central procurement, facilities maintenance scheduling, and administrative cost containment can each contribute incremental basis points of margin protection. Even small gains here can leverage through the P&L given the fixed-cost structure; conversely, any slippage would be visible in the gap between gross profit conversion and EBIT delivery.

Payer mix and Commercial price realization

Last quarter’s payer distribution was anchored by Medicaid at $484.17 million, with Commercial at $211.88 million and Medicare at $125.54 million. For the quarter at hand, the composition and trend in the Commercial book matter for two reasons: pricing dynamics and length-of-stay/utilization patterns. Commercial contracts often allow for structured rate escalators and negotiated adjustments; execution against these terms can cushion unit-cost inflation and offer a path to sustain margins even if overall volumes plateau. The degree of price realization, however, is sensitive to clinical documentation alignment and contract-specific utilization management rules, increasing the importance of disciplined case management and authorization processes.

On the volume side, mix shifts toward higher-acuity Commercial cases can lift revenue per patient day, provided accompanying clinical resources are in place to support throughput. That said, any bottlenecks in admissions or authorizations can compress realized rates if denials or downgrades rise. Keeping referral channels active and ensuring rapid intake coordination helps reduce idle capacity, enabling rate-driven revenue gains to flow through more efficiently. In this context, a favorable mix of Commercial and Medicaid volumes, even if total revenue growth is measured, can deliver incremental margin stabilization relative to conservative EBIT expectations.

Should Commercial volumes hold near last quarter’s $211.88 million baseline and rate actions remain intact, the combined lift from price and documented utilization could mitigate part of the implied year-over-year EBIT compression. Segment-level year-over-year growth detail was not disclosed, but maintaining momentum in Commercial price realization provides one of the clearer levers to offset fixed and semi-variable cost pressure this quarter.

Medicaid-led scale and reimbursement cadence

Medicaid remained the revenue foundation last quarter at $484.17 million, representing approximately 56.86% of the mix. For the current quarter, Medicaid’s performance will reflect sustained throughput and the timing of reimbursement updates flowing through to net revenue per patient day. Operationally, consistent referral pipelines and streamlined admissions are important to keep capacity use balanced and avoid inefficiencies that could erode gross margin. The durability of net revenue capture within Medicaid, in turn, relies on documentation integrity and timely billing to minimize delays that raise working capital friction.

Given Medicaid’s scale, minor changes in rate or length-of-stay assumptions can produce noticeable P&L effects. A steady cadence of reimbursement, aligned with claims processing predictability, supports cash conversion and reduces the need to absorb interim cost volatility. If Medicaid volumes track in line with last quarter while Commercial delivers modest price gains, the blended mix can help defend gross profit dollars even with a conservative EBIT outlook. Conversely, if utilization softness emerges in Medicaid, incremental reliance on Commercial pricing will be needed to maintain the current forecast envelope for revenue and EBIT.

The quarter’s net margin outcome, while not explicitly forecasted, will be an output of how these Medicaid dynamics combine with the expected cost line. Monitoring admission patterns, denial rates, and average daily census during the period provides the earliest read on whether the forecasted revenue slope is likely to be met or if a subsequent rebalancing of mix is required into the next quarter.

Operating expense discipline and liability-cost trajectory

Operating expense controls remain a decisive factor this quarter, especially with consensus embedding an EPS step-down. The company enters the period after resetting expectations for professional and general liability-related costs late last year, which raised the expense run-rate into 2026. The current-quarter projections implicitly assume continued pressure from these items relative to the prior-year comp; that, along with wage/benefit inflation, helps explain the divergence between top-line growth and earnings compression. Actions to reduce variability—claims management rigor, proactive settlements when economically rational, and optimized insurance program structure—can reduce volatility in future quarters, even if the impact is only partially visible in the current period.

Labor remains the largest controllable cost bucket, where tighter scheduling, expanded internal staffing pipelines, and ongoing reduction of premium labor usage can provide incremental savings. Facilities-level initiatives, including energy management and preventative maintenance, can mitigate non-labor operating costs without compromising clinical capacity. If these efforts hold, the implied EBIT margin of roughly 6.40% could prove a floor rather than a ceiling; if not, the risk skews to the downside for profitability while revenue remains near expectations.

Finally, the balance between growth investments and expense containment is in focus. Targeted capacity enhancements and selective program expansions can support medium-term revenue, but in-quarter financials may reflect upfront costs. The challenge is sequencing: emphasizing high-return projects with short payback periods ensures that expense growth does not outpace the revenue base during a quarter where earnings expectations are already conservative.

What is most likely to move the stock on results day

Three elements are poised to exert the most influence on the share price around the print. First, the margin commentary and any quantitative guardrails for liability-related costs in 2026 will frame how investors recalibrate the EPS path beyond this quarter; a clear trajectory for normalization would likely be viewed favorably given the large EPS decline embedded in the near term. Second, the revenue mix and realized pricing in the Commercial channel can validate or challenge the thesis that price actions are offsetting cost inflation; early detail on negotiated rate lifts and their stickiness will be watched closely. Third, any update to operating cadence—admissions flow, bed utilization, and length-of-stay patterns—can signal whether the top-line guide rail is conservative or at risk.

The company’s ability to sustain last quarter’s 42.16% gross margin while moving toward consistent conversion to EBIT will matter more than a one-off revenue variance of a few million dollars. A reiterated path to stabilize earnings—whether through cost management or clearer visibility on liability expenses—could outweigh a modest miss on EPS if revenue is in line. Conversely, if revenue is solid but margins are pressured beyond what consensus embeds, the market may demand firmer commitments on expense containment before rewarding the stock with multiple expansion.

Analyst Opinions

Across the most recent six-month window, published views skew bullish: Buy-rated opinions outnumber bearish views by 3:0, with two additional Hold ratings. The majority side argues that shares can stabilize as execution improves and the expense base becomes more predictable following the late-2025 reset to liability-related costs.

RBC Capital reaffirmed a Buy rating and a $17.00 price target, signaling confidence that current valuation reflects near-term headwinds and that operational progress can drive upside as profitability stabilizes. The stance emphasizes that while earnings for the coming quarter are modeled conservatively, visibility into expense normalization and evidence of steady throughput could catalyze sentiment repair over the next set of results. A reiterated Buy into this setup suggests RBC sees favorable risk-reward once margin variability begins to narrow.

Raymond James maintained a Buy rating with a $30.00 price target, highlighting the importance of execution against core levers—pricing, mix, and cost control—over the next several quarters. The firm’s constructive view implies that even with a projected EBIT decline of 59.98% year over year this quarter, the pathway to recovering earnings power remains intact if management demonstrates consistent delivery on controllable items. Raymond James’ target embeds an assumption that the combination of payer pricing discipline and expense management can re-accelerate earnings growth once the elevated liability cost comparator rolls off.

UBS reiterated a Buy rating with a $31.00 price target, indicating an expectation that current forecasts may be embedding sufficiently cautious assumptions on margins. UBS’s view underscores the importance of clarity on liability cost cadence and the incremental contribution from Commercial price realization, both of which can change the narrative from one of downside protection to one of margin rebuild. The alignment of price targets near $30.00 suggests that multiple expansion is achievable if the revenue base remains firm and the cost curve trends downward.

On the neutral side, Barclays and Cantor Fitzgerald each maintained Hold ratings, reflecting a preference to wait for confirmation that expense and margin volatility are subsiding. These perspectives, however, do not constitute bearish calls and therefore do not alter the majority bullish ratio for this preview. With three Buy ratings versus zero bearish calls in the latest period and two Holds, the balance of institutional commentary leans toward a constructive outlook contingent on execution and clearer expense visibility.

Taken together, the bullish cohort will be focused on three validation points on February 25, 2026: whether Commercial rate realization is tracking as expected, whether operating expense controls are evident in sequential margin trends, and whether management articulates a steady-state liability-cost framework for 2026. If the company delivers on even two of these three, the underlying thesis from the majority side—that the revenue base is resilient and earnings can rebuild as expenses normalize—would gain traction. If, instead, margins are pressured more than anticipated without a commensurate plan to address the cost run-rate, bullish targets would likely be revisited but not necessarily abandoned, given the recognized value in a stable payer-mix platform and the potential for pricing and operational improvements to reassert themselves over subsequent quarters.

In this context, the market’s expectations are measured: modest revenue growth of 2.71% year over year and subdued profitability forecasts leave scope for positive surprise if margin management shows early progress. The decisive factor for the majority of analysts is less about whether the company meets a single-quarter EPS figure and more about whether the path to consistent, predictable profitability is demonstrated through tangible, repeatable operating metrics that investors can underwrite into the forward model.